Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ICVX

Icosavax (ICVX) Stock Price, News & Analysis

Icosavax logo

About Icosavax Stock (NASDAQ:ICVX)

Advanced Chart

Key Stats

Today's Range
$15.31
$15.31
50-Day Range
$15.31
$15.45
52-Week Range
$4.75
$16.10
Volume
N/A
Average Volume
1.22 million shs
Market Capitalization
$766.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Receive ICVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Icosavax and its competitors with MarketBeat's FREE daily newsletter.

ICVX Stock News Headlines

Trump’s tariffs just split the AI market in two
Trump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying on cheap foreign hardware—just saw their costs shoot through the roof. For the other group of AI companies, they were just handed a massive competitive advantage. Make no mistake, AI as a whole is still a game-changer for the global economy. But within the AI sector, Trump’s tariffs have created a huge divergence.
Vaxcyte Inc Ordinary Shares 5VA
NervGen Pharma Corp Ordinary Shares NGEN
Icosavax: Tender Offer With Contingent Value Right
Icosavax CVR Seems Fairly Valued
See More Headlines

ICVX Stock Analysis - Frequently Asked Questions

Icosavax, Inc. (NASDAQ:ICVX) announced its quarterly earnings results on Monday, November, 15th. The company reported ($1.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.81. The business earned $1.83 million during the quarter, compared to analysts' expectations of $3.30 million.

Icosavax (ICVX) raised $150 million in an IPO on Thursday, July 29th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Icosavax investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
11/15/2021
Today
4/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ICVX
Fax
N/A
Employees
60
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-91,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$580,000.00
Price / Cash Flow
N/A
Book Value
$5.47 per share
Price / Book
2.80

Miscellaneous

Free Float
34,767,000
Market Cap
$766.88 million
Optionable
Optionable
Beta
1.28
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:ICVX) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners